InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,122.84
(
1.16%
)
US TECH 100
17,410.80
(
1.96%
)
Dow Jones
38,644.41
(
1.10%
)
Brent Oil
83.24
(
-0.47%
)
Bitcoin
61,670.34
(
4.31%
)
Post# of 251697
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Double_Bagel

Send PM Follow Ignore
Followers 14
Posts 898
Boards Moderated 0
Alias Born 03/07/2011

Double_Bagel

Re: None

Saturday, 08/11/2018 4:17:20 PM

Saturday, August 11, 2018 4:17:20 PM

Post# of 251697
China regulators offer VIP treatment for 48 overseas drugs they’re ready to hustle up with accelerated reviews

Eight months after the Chinese drug administration rolled out its new priority review pathway, its Center for Drug Evaluation has unveiled a list of 48 drugs (which you can see below) approved in the US, EU or Japan that are urgently needed in the clinical setting. As long as the companies can provide evidence that the drug works equally well across races, they can immediately apply for marketing approval with the data they have and will be eligible for priority review.



So, Mayvret is not on this list. Epclusa, Sovaldi, Vosevi and Harvoni are all on this list.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up